MX2023004113A - Metodo para el tratamiento de enfermedades relacionadas con ox40. - Google Patents

Metodo para el tratamiento de enfermedades relacionadas con ox40.

Info

Publication number
MX2023004113A
MX2023004113A MX2023004113A MX2023004113A MX2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A
Authority
MX
Mexico
Prior art keywords
treating
related disease
antibody
present disclosure
atopic dermatitis
Prior art date
Application number
MX2023004113A
Other languages
English (en)
Spanish (es)
Inventor
Yoshinori Nagata
Mitsuo Sato
Kenji Ootaki
Nobuyuki Imai
Munetake SHIMABE
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of MX2023004113A publication Critical patent/MX2023004113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023004113A 2020-10-09 2021-10-08 Metodo para el tratamiento de enfermedades relacionadas con ox40. MX2023004113A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US202163233592P 2021-08-16 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (1)

Publication Number Publication Date
MX2023004113A true MX2023004113A (es) 2023-06-29

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004113A MX2023004113A (es) 2020-10-09 2021-10-08 Metodo para el tratamiento de enfermedades relacionadas con ox40.

Country Status (11)

Country Link
US (1) US20230383001A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225371A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545084A (cg-RX-API-DMAC7.html)
KR (1) KR20230084166A (cg-RX-API-DMAC7.html)
CN (1) CN116437955A (cg-RX-API-DMAC7.html)
AU (1) AU2021358274A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198414A1 (cg-RX-API-DMAC7.html)
IL (1) IL301935A (cg-RX-API-DMAC7.html)
MX (1) MX2023004113A (cg-RX-API-DMAC7.html)
TW (1) TW202222343A (cg-RX-API-DMAC7.html)
WO (1) WO2022075476A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Methods of treating alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるt細胞の減少を抑制するために使用されるt細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026145427A1 (en) * 2024-12-30 2026-07-09 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Bispecific antibodies targeting ox40 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
RU2759630C2 (ru) * 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
TWI787203B (zh) * 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Also Published As

Publication number Publication date
US20230383001A1 (en) 2023-11-30
CA3198414A1 (en) 2022-04-14
JP2023545084A (ja) 2023-10-26
TW202222343A (zh) 2022-06-16
KR20230084166A (ko) 2023-06-12
AU2021358274A1 (en) 2023-05-25
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
IL301935A (en) 2023-06-01
AU2021358274A9 (en) 2024-05-30
EP4225371A1 (en) 2023-08-16
CN116437955A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
PH12021550023A1 (en) Humanized anti-tau antibodies
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
PH12019500177A1 (en) Treatment and prevention of sleep disorders
ZA202005388B (en) Methods of treating ulcerative colitis
MX373301B (es) Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
NI201200171A (es) Anticuerpos hacia gdf8 humano
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
AR101740A1 (es) Terapia de combinación y composiciones
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
WO2016127059A3 (en) Light inhibitors for scleroderma and skin fibrotic disease treatment
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
MX2018011025A (es) Metodos para tratar o prevenir la enfermedad del injerto contra huésped.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2022013557A (es) Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer.
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
EA201590884A1 (ru) Способы лечения заболеваний печени
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
MY207627A (en) Methods of treating psoriasis
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo
MX2019004200A (es) Terapia de combinacion.